Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 8/20 | 0.40 |
| ▸ | NAALAD2 | Q9Y3Q0 | 2/20 | 0.40 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.40 |
| ▸ | NOD1 | Q9Y239 | 2/20 | 0.35 |
| ▸ | GRN | P28799 | 3/20 | 0.35 |
| ▸ | SORT1 | Q99523 | 3/20 | 0.35 |
| ▸ | GGH | Q92820 | 1/20 | 0.32 |
| ▸ | MME | P08473 | 1/20 | 0.31 |
| ▸ | ACE | P12821 | 1/20 | 0.31 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26297290 | 0.88 | FOLH1 (0.38) | FOLH1NAALAD2RIMKLANOD1GRN | |
| SCHEMBL29311200 | 0.85 | NOD1 (0.38) | FOLH1NAALAD2RIMKLANOD1GRN | |
| SCHEMBL27015839 | 0.83 | FOLH1 (0.42) | FOLH1NAALAD2RIMKLANOD1GRN | |
| SCHEMBL20100669 | 0.78 | MAPT (0.50) | FOLH1NAALAD2RIMKLANOD1 | |
| SCHEMBL27115186 | 0.76 | NOD1 (0.47) | FOLH1NAALAD2RIMKLANOD1GRN | |
| SCHEMBL22054340 | 0.76 | FOLH1 (0.72) | FOLH1NAALAD2RIMKLA | |
| SCHEMBL22054657 | 0.76 | FOLH1 (0.72) | FOLH1NAALAD2RIMKLA | |
| SCHEMBL20661443 | 0.74 | NOD1 (0.54) | FOLH1NAALAD2RIMKLANOD1 | |
| SCHEMBL22315887 | 0.73 | FOLH1 (0.38) | FOLH1NAALAD2RIMKLANOD1GGH | |
| SCHEMBL2552007 | 0.73 | FOLH1 (0.62) | FOLH1NAALAD2RIMKLAGGH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240226225-A1 | CONJUGATED HEPCIDIN MIMETICS | PROTAGONIST THERAPEUTICS, INC. (US) | 2024-07-11 | — | — | US | disclosed |
| US-20240066131-A1 | CONJUGATED HEPCIDIN MIMETICS | PROTAGONIST THERAPEUTICS, INC. (US) | 2024-02-29 | — | — | US | disclosed |
| US-20230295259-A1 | Conjugated Hepcidin Mimetics | PROTAGONIST THERAPEUTICS, INC. | 2023-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295259-A1 | Conjugated Hepcidin Mimetics | HAMP, VIP, HDGF | FOLH1 49/4885NAALAD2 1213/4885RIMKLA 2147/4885 |
| US-20240066131-A1 | CONJUGATED HEPCIDIN MIMETICS | HAMP, VIP, HDGF | FOLH1 49/4885NAALAD2 1213/4885RIMKLA 2147/4885 |
| US-20240226225-A1 | CONJUGATED HEPCIDIN MIMETICS | HAMP, SLC40A1, FTH1 | FOLH1 109/4885NAALAD2 2752/4885RIMKLA 1452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.